We are proud to announce the USPTO patent covering our 1st Generation micro blood collection device, HemaXis DB, has been fully granted under “Device and Method for Dried Fluid Spot Analysis”. This further secures the market potential for our innovative HemaXis™ platform and the opportunity to leverage its microfluidic based technology. See HemaXis DB in action below and then register with us under the Connect menu option to order a free evaluation kit.
HemaXis DB is a FDA Class 1 medical device. HemaXis DX is in development and for research purposes only. Use of HemaXis devices in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with local regulatory requirements.
By using this website you are agreeing to our Terms and Conditions.